tiprankstipranks

Mohamad Makhzoumi Insider Profile

4 Followers
Mohamad Makhzoumi, Former 10% Owner at Regulus, holds 1.30M shares in Korro Bio (Ticker: KRRO), holds 7.39M shares in SpyGlass Pharma (Ticker: SGP), holds 0.00 shares in NeueHealth Inc (Ticker: NEUE). Most recently, Mohamad Makhzoumi Bought ― shares of Korro Bio on Mar 12, 2026 for an estimated value of $2.30M.
tipranks
Mohamad Makhzoumi

Mohamad Makhzoumi
Regulus (RGLS)
Former 10% Owner

Ranked #103,333 out of 106,487 Corporate Insiders

Profitable Transactions

22%
8 out of 36 Profitable Transactions

Average Return

-33.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$4B
46.34%
15.21%
11.63%
5.87%
20.96% Others
A breakdown of Mohamad Makhzoumi's holdings

Insider Roles

Robinhood
(HOOD)
Director
Arcellx Inc
(ACLX)
Ten Percent Owner
IonQ
(IONQ)
Ten Percent Owner
Mirum Pharmaceuticals
(MIRM)
Ten Percent Owner
+9 other positions
Roles that Mohamad Makhzoumi holds in companies

Most Profitable Insider Trade

Stock:
Eargo
(EAR)
Rating:Informative Sell
Date:May 26, 2021 - May 26, 2022
Return:+96.10%
The most profitable trade made by Mohamad Makhzoumi

Mohamad Makhzoumi's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
RGLS
Regulus
May 09, 2019
Informative Buy
1.23M
$16.75M
AVEO
AVEO Pharma
Oct 21, 2022
Uninformative Buy
$13.70K
Genocea Biosciences
May 26, 2022
Ten Percent Owner
Informative Sell
711.52K
Trevi Therapeutics
Apr 13, 2022
Ten Percent Owner
Informative Buy
6.80M
$148.95M
Mirum Pharmaceuticals
Jun 15, 2023
Ten Percent Owner
Uninformative Buy
$210.21M
Ardelyx
Dec 09, 2019
Ten Percent Owner
Uninformative Buy
2.50M
$39.06M
AKUS
AKOUOS
Dec 02, 2022
Uninformative Sell
$0.00
Nkarta
Jul 16, 2020
Ten Percent Owner
Uninformative Buy
$6.53M
INZY
Inozyme Pharma
Jul 28, 2020
Uninformative Buy
$9.75M
MTCR
Metacrine
Dec 27, 2021
Informative Sell
493.91K
$1.49M
EAR
Eargo
May 26, 2021
Uninformative Buy
$11.62M
NEUE
NeueHealth Inc
Oct 06, 2025
Uninformative Buy
39.43K
$0.00
Monte Rosa Therapeutics
Jun 30, 2021
Ten Percent Owner
Uninformative Buy
$131.69M
Robinhood
May 04, 2022
Director
Uninformative Buy
$1.66B
IonQ
Nov 18, 2022
Ten Percent Owner
Uninformative Buy
$416.45M
Arcellx Inc
Dec 22, 2022
Ten Percent Owner
Uninformative Buy
$544.79M
Savara
Jul 19, 2023
Ten Percent Owner
Informative Buy
1000.00K
$141.44M
Korro Bio
Mar 12, 2026
Ten Percent Owner
Informative Buy
2.30M
$18.05M
MBX Biosciences, Inc.
Sep 17, 2024
Ten Percent Owner
Uninformative Buy
$109.12M
SpyGlass Pharma
Feb 11, 2026
Ten Percent Owner
Uninformative Buy
$155.76M
List of latest transactions for each holding click on a transaction to see Mohamad Makhzoumi's performance on stock

Mohamad Makhzoumi insider profile FAQ

What is the percentage of profitable transactions made by Mohamad Makhzoumi?
The percentage of profitable transactions made by Mohamad Makhzoumi is 22%.
    What is the average return per transaction made by Mohamad Makhzoumi?
    The average return per transaction made by Mohamad Makhzoumi is -33.20%.
      What stocks does Mohamad Makhzoumi hold?
      Mohamad Makhzoumi holds: RGLS, AVEO, GNCAQ, TRVI, MIRM, ARDX, AKUS, NKTX, INZY, MTCR, EAR, NEUE, GLUE, HOOD, IONQ, ACLX, SVRA, KRRO, MBX, SGP stocks.
        What was Mohamad Makhzoumi’s latest transaction?
        Mohamad Makhzoumi latest transaction was an Informative Buy of $2.30M.
          What was Mohamad Makhzoumi's most profitable transaction?
          Mohamad Makhzoumi’s most profitable transaction was an Informative Sell of EAR stock on May 26, 2021. The return on the trade was 96.10%.
            What is Mohamad Makhzoumi's role in Regulus?
            Mohamad Makhzoumi's role in Regulus is Former 10% Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.